OSR Health (OSRHW) Liabilities and Shareholders Equity (2021 - 2026)
OSR Health (OSRHW) posted Liabilities and Shareholders Equity of $172.2 million for Q1 2026, up 0.55% sequentially from $171.2 million in Q4 2025, and down 1.35% YoY from $174.6 million in Q1 2025.
OSR Health (OSRHW) Liabilities and Shareholders Equity (2021 - 2026) Analysis & Trends
OSR Health has reported Liabilities and Shareholders Equity for 6 years, with the latest figure at $172.2 million in Q1 2026.
- Quarterly Liabilities and Shareholders Equity fell 1.35% year-over-year to $172.2 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $706.1 million (up 80.43% YoY) and the FY2025 annual result came in at $171.2 million, down 2.28% from the prior year.
- Liabilities and Shareholders Equity grew to $172.2 million in Q1 2026 per OSRHW's latest filing, from $171.2 million in the prior quarter.
- Over five years, Liabilities and Shareholders Equity peaked at $185.4 million in Q2 2025 and troughed at $1.2 million in Q4 2022.
- A 5-year average of $99.1 million and a median of $71.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
- The sharpest annual moves came in 2023 and 2024: Liabilities and Shareholders Equity soared 2887.94% in 2023, then sank 71.14% in 2024.
- Over 5 years, Liabilities and Shareholders Equity stood at $1.2 million in 2022, then jumped by 2887.94% to $36.6 million in 2023, then jumped by 378.43% to $175.2 million in 2024, then declined by 2.28% to $171.2 million in 2025, then increased by 0.55% to $172.2 million in 2026.
- According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $172.2 million, $171.2 million, and $177.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Liabilities and Shareholders Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.97 Bn | 131.12 Bn | 2.84 Bn | 27.42 Bn |
| 2 | Regeneron Pharmaceuticals | 85.15 Bn | 77.15 Bn | 3.93 Bn | 41.73 Bn |
| 3 | Argenx Se | 62.84 Bn | 57.65 Bn | 1.37 Bn | 10.03 Bn |
| 4 | Moderna | 55.74 Bn | 50.60 Bn | 52.00 Mn | 10.96 Bn |
| 5 | BeOne Medicines | 41.53 Bn | 36.43 Bn | 1.53 Bn | 9.18 Bn |
| 6 | Alnylam Pharmaceuticals | 31.60 Bn | 28.29 Bn | 992.69 Mn | 5.56 Bn |
| 7 | BioNTech SE | 27.32 Bn | 8.93 Bn | 668.28 Mn | 25.60 Bn |
| 8 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 19.82 Bn |
| 9 | Insmed | 26.99 Bn | 25.83 Bn | 358.27 Mn | 2.10 Bn |
| 10 | OSR Health | 1.40 Mn | 20.39 Mn | 86,605.00 | 166.62 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 172.19 Mn |
| Dec 31, 2025 | 171.24 Mn |
| Sep 30, 2025 | 177.29 Mn |
| Jun 30, 2025 | 185.42 Mn |
| Mar 31, 2025 | 174.55 Mn |
| Dec 31, 2024 | 175.24 Mn |
| Sep 30, 2024 | 20.93 Mn |
| Jun 30, 2024 | 20.63 Mn |
| Mar 31, 2024 | 37.27 Mn |
| Dec 31, 2023 | 36.63 Mn |
| Sep 30, 2023 | 72.14 Mn |
| Jun 30, 2023 | 71.49 Mn |
| Mar 31, 2023 | 71.06 Mn |
| Dec 31, 2022 | 1.23 Mn |
| Dec 31, 2021 | 705,087.00 |